Cargando…
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma
Every year, 31 230 men and women are diagnosed with colorectal carcinoma, and up to 60% of these will ultimately develop advanced disease. However, there is little information to identify which patients are most likely to benefit from palliative chemotherapy. This analysis is unique in evaluating ho...
Autores principales: | Assersohn, L, Norman, A, Cunningham, D, Benepal, T, Ross, P J, Oates, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362782/ https://www.ncbi.nlm.nih.gov/pubmed/10206296 http://dx.doi.org/10.1038/sj.bjc.6990287 |
Ejemplares similares
-
Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma
por: Ford, H E R, et al.
Publicado: (2000) -
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer
por: Chau, I, et al.
Publicado: (2001) -
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
por: Wittke, F, et al.
Publicado: (1999) -
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
por: Rao, S, et al.
Publicado: (2004) -
Collagen type XVIII/endostatin is differentially expressed in primary and metastatic colorectal cancers and ovarian carcinomas
por: Guenther, U, et al.
Publicado: (2001)